Total Payments
$791,422
2024 Payments
$57,557
Companies
49
Transactions
1,363
Medicare Patients
4,247
Medicare Billing
$864,144
Payment Breakdown by Category
Other$362,648 (45.8%)
Consulting$248,313 (31.4%)
Research$88,132 (11.1%)
Food & Beverage$52,781 (6.7%)
Travel$39,318 (5.0%)
Gifts$146.87 (0.0%)
Education$83.46 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $248,313 | 158 | 31.4% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $138,504 | 52 | 17.5% |
| Honoraria | $89,386 | 43 | 11.3% |
| Unspecified | $88,132 | 9 | 11.1% |
| Compensation for serving as faculty or as a speaker for a medical education program | $70,475 | 19 | 8.9% |
| Compensation for serving as faculty or as a speaker for a non-accredited and noncertified continuing education program | $64,220 | 23 | 8.1% |
| Food and Beverage | $52,781 | 869 | 6.7% |
| Travel and Lodging | $39,318 | 182 | 5.0% |
| Gift | $146.87 | 4 | 0.0% |
| Education | $83.46 | 3 | 0.0% |
| Entertainment | $63.56 | 1 | 0.0% |
Payments by Type
General
$703,290
1,354 transactions
Research
$88,132
9 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Bausch & Lomb Americas Inc. | $101,048 | 121 | $0 (2024) |
| Bausch & Lomb, a division of Bausch Health US, LLC | $90,744 | 154 | $0 (2021) |
| Shire North American Group Inc | $72,539 | 126 | $0 (2019) |
| Bausch Health US, LLC | $68,159 | 10 | $0 (2020) |
| LENSAR, Inc. | $64,159 | 68 | $0 (2024) |
| Oyster Point Pharma, Inc. | $53,715 | 82 | $0 (2024) |
| Omeros Corporation | $35,099 | 43 | $0 (2021) |
| Ocular Therapeutix, Inc. | $34,172 | 60 | $0 (2024) |
| Allergan, Inc. | $33,660 | 73 | $0 (2022) |
| SUN PHARMACEUTICAL INDUSTRIES INC. | $33,160 | 87 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $57,557 | 113 | Bausch & Lomb Americas Inc. ($34,317) |
| 2023 | $112,191 | 147 | Bausch & Lomb Americas Inc. ($50,503) |
| 2022 | $102,414 | 207 | Oyster Point Pharma, Inc. ($25,801) |
| 2021 | $72,291 | 154 | Omeros Corporation ($12,240) |
| 2020 | $65,523 | 109 | Novartis Pharmaceuticals Corporation ($11,416) |
| 2019 | $168,165 | 277 | Bausch & Lomb, a division of Bausch Health US, LLC ($41,103) |
| 2018 | $147,107 | 203 | Bausch & Lomb, a division of Bausch Health US, LLC ($43,674) |
| 2017 | $66,174 | 153 | Shire North American Group Inc ($29,786) |
All Payment Transactions
1,363 individual payment records from CMS Open Payments — Page 1 of 55
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/31/2024 | Bausch & Lomb Americas Inc. | MIEBO (Drug), XIIDRA | Compensation for serving as faculty or as a speaker for a medical education program | Cash or cash equivalent | $6,800.00 | General |
| Category: Ophthalmology | ||||||
| 12/23/2024 | Bausch & Lomb Americas Inc. | ENVISTA ENVY (Device) | Food and Beverage | In-kind items and services | $25.89 | General |
| Category: Ophthalmology | ||||||
| 12/20/2024 | Oyster Point Pharma, Inc. | TYRVAYA (Drug) | Food and Beverage | In-kind items and services | $125.00 | General |
| Category: Dry eyes | ||||||
| 12/11/2024 | Bausch & Lomb Americas Inc. | MIEBO (Drug), XIIDRA | Travel and Lodging | Cash or cash equivalent | $421.95 | General |
| Category: Ophthalmology | ||||||
| 12/11/2024 | Bausch & Lomb Americas Inc. | MIEBO (Drug), XIIDRA | Travel and Lodging | Cash or cash equivalent | $339.37 | General |
| Category: Ophthalmology | ||||||
| 12/11/2024 | Bausch & Lomb Americas Inc. | MIEBO (Drug), XIIDRA | Food and Beverage | In-kind items and services | $117.67 | General |
| Category: Ophthalmology | ||||||
| 12/11/2024 | Bausch & Lomb Americas Inc. | MIEBO (Drug), XIIDRA | Travel and Lodging | Cash or cash equivalent | $62.52 | General |
| Category: Ophthalmology | ||||||
| 12/11/2024 | Bausch & Lomb Americas Inc. | MIEBO (Drug), XIIDRA | Travel and Lodging | Cash or cash equivalent | $60.00 | General |
| Category: Ophthalmology | ||||||
| 12/11/2024 | Bausch & Lomb Americas Inc. | MIEBO (Drug), XIIDRA | Travel and Lodging | Cash or cash equivalent | $42.88 | General |
| Category: Ophthalmology | ||||||
| 12/11/2024 | Bausch & Lomb Americas Inc. | MIEBO (Drug), XIIDRA | Food and Beverage | In-kind items and services | $26.11 | General |
| Category: Ophthalmology | ||||||
| 12/11/2024 | Harrow Eye, LLC | VEVYE (Drug) | Food and Beverage | In-kind items and services | $11.57 | General |
| Category: OPTOMETRY | ||||||
| 11/26/2024 | Bausch & Lomb Americas Inc. | MIEBO (Drug), XIIDRA | Compensation for serving as faculty or as a speaker for a medical education program | Cash or cash equivalent | $3,400.00 | General |
| Category: Ophthalmology | ||||||
| 11/26/2024 | Bausch & Lomb Americas Inc. | ENVISTA ENVY (Device) | Food and Beverage | In-kind items and services | $105.75 | General |
| Category: Ophthalmology | ||||||
| 11/23/2024 | Bausch & Lomb Americas Inc. | VICTUS (Device) | Food and Beverage | In-kind items and services | $49.30 | General |
| Category: Ophthalmology | ||||||
| 11/20/2024 | Tarsus Pharmaceuticals, Inc. | XDEMVY (Drug) | Food and Beverage | In-kind items and services | $24.73 | General |
| Category: DEMODEX BLEPHARITIS | ||||||
| 11/19/2024 | NEW WORLD MEDICAL,INC. | Kahook Dual Blade (Device), Clearpath, Ahmed Glaucoma Valve | Food and Beverage | In-kind items and services | $3.39 | General |
| Category: Ophthalmology | ||||||
| 11/12/2024 | Bausch & Lomb Americas Inc. | MIEBO (Drug), XIIDRA | Food and Beverage | In-kind items and services | $124.16 | General |
| Category: Ophthalmology | ||||||
| 11/12/2024 | Bausch & Lomb Americas Inc. | MIEBO (Drug), XIIDRA | Travel and Lodging | Cash or cash equivalent | $18.81 | General |
| Category: Ophthalmology | ||||||
| 11/12/2024 | Bausch & Lomb Americas Inc. | MIEBO (Drug), XIIDRA | Travel and Lodging | Cash or cash equivalent | $17.81 | General |
| Category: Ophthalmology | ||||||
| 11/09/2024 | NEW WORLD MEDICAL,INC. | Kahook Dual Blade (Device), Clearpath, Ahmed Glaucoma Valve | Food and Beverage | In-kind items and services | $53.48 | General |
| Category: Ophthalmology | ||||||
| 11/09/2024 | Harrow Eye, LLC | — | Food and Beverage | In-kind items and services | $21.54 | General |
| 11/08/2024 | Harrow Eye, LLC | — | Food and Beverage | In-kind items and services | $280.72 | General |
| 11/08/2024 | Tarsus Pharmaceuticals, Inc. | XDEMVY (Drug) | Food and Beverage | In-kind items and services | $47.08 | General |
| Category: DEMODEX BLEPHARITIS | ||||||
| 11/08/2024 | SUN PHARMACEUTICAL INDUSTRIES INC. | Cequa (Drug) | Food and Beverage | In-kind items and services | $16.43 | General |
| Category: Ophthalmology | ||||||
| 10/31/2024 | ABBVIE INC. | LUMIGAN (Drug) | Food and Beverage | In-kind items and services | $34.40 | General |
| Category: EYE CARE | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| BAUSCH & LOMB OVD DISPERSIVE DVISC40 STUDY S877 | Bausch Health US, LLC | $34,583 | 3 |
| A STUDY TO DOCUMENT THE SAFETY AND EFFECTIVENESS OF A NEW OPHTHALMIC VISCOSURGICAL DEVICE OVD WHEN COMPARED TO A CONTROL OVD | Bausch Health US, LLC | $33,299 | 3 |
| Refractive Targets & Visual Outcomes | Johnson & Johnson Surgical Vision, Inc. | $12,500 | 1 |
| OUTCOMES RESEARCH | Novartis Pharmaceuticals Corporation | $7,000 | 1 |
| Publication support research related | Novartis Pharma AG | $750.00 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 13 | 876 | 1,227 | $598,349 | $176,925 |
| 2022 | 15 | 1,088 | 1,445 | $820,532 | $211,384 |
| 2021 | 10 | 1,100 | 1,576 | $1.4M | $263,006 |
| 2020 | 10 | 1,183 | 1,654 | $1.2M | $212,829 |
Total Patients
4,247
Total Services
5,902
Medicare Billing
$864,144
Procedure Codes
48
All Medicare Procedures & Services
48 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 66984 | Removal of cataract with insertion of prosthetic lens | Facility | 2023 | 103 | 172 | $221,353 | $68,063 | 30.7% |
| 66821 | Removal of recurring cataract in lens capsule using a laser | Office | 2023 | 133 | 215 | $189,804 | $58,269 | 30.7% |
| 99212 | Established patient office or other outpatient visit, 10-19 minutes | Office | 2023 | 187 | 245 | $36,578 | $10,464 | 28.6% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 107 | 155 | $36,916 | $10,459 | 28.3% |
| 66982 | Complex removal of cataract with insertion of prosthetic lens | Facility | 2023 | 15 | 18 | $31,703 | $9,857 | 31.1% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 78 | 96 | $32,295 | $8,750 | 27.1% |
| 92134 | Imaging of retina | Office | 2023 | 62 | 83 | $8,814 | $2,681 | 30.4% |
| 92136 | Measurement of corneal curvature and depth of eye | Office | 2023 | 82 | 96 | $9,422 | $2,538 | 26.9% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 22 | 22 | $9,642 | $2,346 | 24.3% |
| 92014 | Established patient complete exam of visual system | Office | 2023 | 14 | 14 | $4,634 | $1,487 | 32.1% |
| 68841 | Insertion of drug delivery implant into tear duct of eye | Facility | 2023 | 51 | 83 | $13,531 | $1,026 | 7.6% |
| 92083 | Exam of visual field with extended testing | Office | 2023 | 11 | 14 | $2,306 | $604.21 | 26.2% |
| 92133 | Imaging of optic nerve | Office | 2023 | 11 | 14 | $1,350 | $381.72 | 28.3% |
| 66984 | Removal of cataract with insertion of prosthetic lens | Facility | 2022 | 139 | 234 | $380,762 | $94,457 | 24.8% |
| 66821 | Removal of recurring cataract in lens capsule using a laser | Office | 2022 | 132 | 206 | $195,742 | $56,903 | 29.1% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 124 | 134 | $42,606 | $12,107 | 28.4% |
| 66982 | Complex removal of cataract with insertion of prosthetic lens | Facility | 2022 | 15 | 19 | $33,544 | $10,716 | 31.9% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 119 | 142 | $33,917 | $9,638 | 28.4% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 70 | 70 | $27,824 | $7,731 | 27.8% |
| 99212 | Established patient office or other outpatient visit, 10-19 minutes | Office | 2022 | 103 | 119 | $18,064 | $5,426 | 30.0% |
| 92136 | Measurement of corneal curvature and depth of eye | Office | 2022 | 98 | 117 | $15,522 | $3,789 | 24.4% |
| 92134 | Imaging of retina | Office | 2022 | 91 | 98 | $11,244 | $3,138 | 27.9% |
| 83861 | Microfluid analysis of tears | Office | 2022 | 47 | 116 | $14,500 | $2,576 | 17.8% |
| 68841 | Insertion of drug delivery implant into tear duct of eye | Facility | 2022 | 79 | 117 | $34,654 | $1,443 | 4.2% |
| 92083 | Exam of visual field with extended testing | Office | 2022 | 20 | 21 | $3,443 | $963.61 | 28.0% |
About Dr. Mitchell Jackson, MD
Dr. Mitchell Jackson, MD is a Ophthalmology healthcare provider based in Lake Villa, Illinois. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 01/18/2007. The National Provider Identifier (NPI) number assigned to this provider is 1902958929.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Mitchell Jackson, MD has received a total of $791,422 in payments from pharmaceutical and medical device companies, with $57,557 received in 2024. These payments were reported across 1,363 transactions from 49 companies. The most common payment nature is "Consulting Fee" ($248,313).
As a Medicare-enrolled provider, Jackson has provided services to 4,247 Medicare beneficiaries, totaling 5,902 services with total Medicare billing of $864,144. Data is available for 4 years (2020–2023), covering 48 distinct procedure/service records.
Ad
Practice Information
- Specialty Ophthalmology
- Location Lake Villa, IL
- Active Since 01/18/2007
- Last Updated 01/09/2014
- Taxonomy Code 207W00000X
- Entity Type Individual
- NPI Number 1902958929
Products in Payments
- XIIDRA (Drug) $77,955
- MIEBO (Drug) $64,520
- LENSAR LASER SYSTEM (Device) $64,159
- TYRVAYA (Drug) $53,715
- DVISC40 (Device) $37,074
- DEXTENZA (Drug) $32,370
- OMIDRIA (Drug) $25,943
- VUITY (Drug) $23,164
- STELLARIS PC (Device) $21,805
- PROLENSA (Drug) $20,385
- STELLARIS ELITE (Device) $19,402
- ARTEVO 800 (Device) $19,182
- DEXYCU (Drug) $16,912
- LOTEMAX GEL (Drug) $15,754
- Cequa (Drug) $13,620
- iDesign Advanced Wavescan Studio (Device) $12,500
- LOTEMAX SM (Drug) $11,761
- Omidria (Drug) $10,958
- CEQUA (Drug) $8,884
- ENVISTA TORIC (Device) $7,261
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.